| COVID-19 |
1 |
1 |
| Hospital |
0 |
0.83 |
| Revenue and Practice Management |
0 |
0.9 |
| Antiviral Agents |
0 |
0.37 |
| Clinical Research |
0 |
0.28 |
| Food and Drug Administration (FDA) |
0 |
0.75 |
| Health Care Quality, Access, and Evaluation |
0 |
0.18 |
| Social Determinants of Health |
0 |
0.12 |
| Allergy |
0 |
0.09 |
| Clinical Guidelines |
0 |
0.09 |
| Grant |
0 |
0.09 |
| Intravenous |
0 |
0.09 |
| Iowa |
0 |
0.09 |
| Microbiology |
0 |
0.09 |
| Pandemic |
0 |
0.09 |
| Salary and Compensation |
0 |
0.09 |
| Severe Acute Respiratory Syndrome (SARS) |
0 |
0.09 |
| Acute Respiratory Distress Syndrome |
0 |
0.06 |
| Chronic Obstructive Pulmonary Disease |
0 |
0.06 |
| Mechanical Ventilation |
0 |
0.06 |
| Microbiome |
0 |
0.06 |